Relonchem Limited receives Marketing Authorization for its products

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for the below-mentioned products from UK MHRA:

1. Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets
2. Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets
3. Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 184.10 as compared to the previous close of Rs. 178.30. The total number of shares traded during the day was 71594 in over 1494 trades.

The stock hit an intraday high of Rs. 184.95 and intraday low of 180.30. The net turnover during the day was Rs. 13072502.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Relonchem MarketingAuthorization UKMHRA